Breast cancer arising in a BRCA-mutated background: therapeutic implications from an animal model and drug development
Authors:
Open Access
- 15 January 2009
- journal article
- review article
- Published by Elsevier in Annals of Oncology
- Vol. 20 (4) , 609-614
Abstract
To date, the presence of a hereditary background has not influenced the selection of drug treatment in breast cancer. However, increasingly, negative hormone receptors and Her2 (often referred to as ‘triple negative’) or a medullary carcinoma histology has been reported in BRCA mutation carriers. Accordingly, such patients are often considered for adjuvant protocols based on chemotherapy (and not based on endocrine manipulations or trastuzumab). Mouse models introducing a conditional BRCA-null expression in the breast have recently provided powerful support for cisplatin-based treatment and have implications for the design of adjuvant studies in these patients.Keywords
This publication has 46 references indexed in Scilit:
- Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative PhenotypeClinical Cancer Research, 2008
- Triple Negative Breast Carcinoma and the Basal Phenotype: From Expression Profiling to Clinical PracticeAdvances in Anatomic Pathology, 2007
- Use of immunohistochemical markers can refine prognosis in triple negative breast cancerBMC Cancer, 2007
- Triple-negative breast cancer: therapeutic optionsThe Lancet Oncology, 2007
- Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importanceEuropean Journal of Cancer, 2006
- Phenotypic evaluation of the basal-like subtype of invasive breast carcinomaLaboratory Investigation, 2005
- Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast CarcinomaClinical Cancer Research, 2004
- Repeated observation of breast tumor subtypes in independent gene expression data setsProceedings of the National Academy of Sciences, 2003
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences, 2001
- Molecular portraits of human breast tumoursNature, 2000